Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy

Abstract Delandistrogene moxeparvovec is an rAAVrh74 vector-based gene transfer therapy that delivers a transgene encoding delandistrogene moxeparvovec micro-dystrophin, an engineered, functional form of dystrophin shown to stabilize or slow disease progression in DMD. It is approved in the US and i...

Full description

Bibliographic Details

Published in:	Scientific Reports
Main Authors:	Rachael A. Potter, Ida H. Moeller, Sohrab Khan, Hélène Haegel, Andreas Hollenstein, Guido Steiner, Christoph Wandel, Alexander P. Murphy, Damon R. Asher, Emanuel Palatinsky, Danielle A. Griffin, Stefanie Mason, Susan T. Iannaccone, Craig M. Zaidman, Louise R. Rodino-Klapac
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-01-01
Subjects:	AAV vector Delandistrogene moxeparvovec Duchenne muscular dystrophy Dystrophin Gene transfer therapy Immune-mediated myositis
Online Access:	https://doi.org/10.1038/s41598-024-84077-w